Hyderabad-based Indian Immunologicals Limited announces strategic partnership with CIFE Mumbai, Indian Council of Agricultural Research Institutes
Posted Date – Mon, 11/28/22 at 10:46pm
Photo: Twitter/Indian Immunologicals Limited
Hyderabad: Hyderabad-based Indian Immunologicals Limited (IIL) has pioneered a partnership with a national research institute to produce the country’s first vaccine against a bacterial disease in freshwater fish.
To develop such vaccines that can be scaled up at the commercial level, the leading vaccine manufacturer from Hyderabad on Monday announced a strategic partnership with Mumbai’s Central Institute of Fisheries Education (CIFE), a division of the Indian Council of Agricultural Research (CIFE). ICAR) Institute.
Currently, there are no commercial fish vaccines in India that can prevent major aquaculture infections. As a result, the aquaculture industry in the country suffers economically from infections caused by a wide range of bacteria, viruses, fungi, and other pathogens.
As part of the collaboration, CIFE will provide technology for two inactivated bacterial vaccines – one for columnar disease, a serious disease affecting many freshwater fish species, and the other for Edward’s disease. Both diseases are extremely common in freshwater fish and are thought to be ubiquitous, IIL and CIFE officials said.
Due to the lack of a vaccine, such infections are controlled with varying degrees of success with anti-infective drugs and other conventional measures. “We were the first company in India to enter the fish vaccine space and are working on launching more and more products for the aquaculture market to help shrimp and fish farmers increase productivity and protect fish stocks from various diseases. violations,” said IIL Managing Director Dr K Anand. Kumar said.
Dr. Priyabrata Pattnaik, deputy general manager of IIL, said the company is planning to introduce vaccines and immune stimulants through technology transfer from various fisheries research institutes under ICAR. The IIL is currently evaluating several candidate fish vaccines for commercialization. “The introduction of such vaccines will have a positive impact on reducing the misuse of chemical or antibiotic treatments. This in turn will help reduce antimicrobial resistance,” he said.
ICAR-CIFE Director and Vice Chancellor Dr CN Ravishankar said the collaboration between CIFE and IIL was crucial in the development of India’s first bacterial fish vaccine.
